Oncolytic viral therapeutics with both of tumor versatility and selectivity by combining of genes acting co-operatively

As we learn more about cancer, treatment options are also increasing in sophistication. Targeted cancer therapies have been developed that can specifically target cancerous cells and block their proliferation. However, there is scope to improve the effects of such therapies. Researchers from Yonsei University of South Korea have invented a gene complex that greatly increases antitumor activity. This complex comprises of four genes: granulocyte-macrophage stimulating factor (or GM-CSF), an Flt3L-TRAIL fusion gene, short-hairpin RNA (or shRNA) that inhibits TGF-beta expression, and shRNA that inhibits HSP expression. For more information, please click here.

As we learn more about cancer, treatment options are also increasing in sophistication. Targeted cancer therapies have been developed that can specifically target cancerous cells and block their proliferation. However, there is scope to improve the effects of such therapies. Researchers from Yonsei University of South Korea have invented a gene complex that greatly increases antitumor activity. This complex comprises of four genes: granulocyte-macrophage stimulating factor (or GM-CSF), an Flt3L-TRAIL fusion gene, short-hairpin RNA (or shRNA) that inhibits TGF-beta expression, and shRNA that inhibits HSP expression. For more information, please click here.